PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies.
PHEDRA (Platform for Haematology in EMEA: Data for Real World Analysis) is a unique, noninterventional project based on secondary data collection from real-world (RW) patient-level (health record) databases to understand treatment patterns in hematological malignancies. It compares ibrutinib's effectiveness with alternative treatments using RW data (RWD) and randomized clinical trials data. RWD are cleaned, validated, harmonized into a Common Data Model, and analyzed statistically alongside randomized clinical trial data. Treatment outcomes include overall and progression-free survival. To date, RWD (four databases) are available for 2840 patients in three indications, collected between 1990 and 2017. PHEDRA is an innovative approach to generate evidence to inform optimal treatment decisions in RW settings.